Skip to main content
. Author manuscript; available in PMC: 2014 Apr 26.
Published in final edited form as: Vaccine. 2013 Mar 14;31(18):2238–2245. doi: 10.1016/j.vaccine.2013.03.003

Fig. 4. Tim-3 blockade improves IL-12p35 and inhibits IL-23p19 productions by CD14+ monocytes, leading to reduction of TH17 cells in HCV-infected HBV-NR.

Fig. 4

A) Purified CD14+ monocytes from HCV-infected HBV-NR and HBV-R or HS were incubated with αTim-3 and control IgG antibody for 72h; then stimulated with LPS/R848 for 6h, followed by flow cytometry analysis of IL-12p35 and IL-23p19 expressions. Representative dot plots and summary data measuring IL-12p35 and IL-23p19 productions by CD14+ monocytes in HCV-infected HBV-NR versus HBV-R or HS with the blockade of Tim-3 or IgG antibody are shown. *P<0.05; **P<0.01; NS = no significance. B) PBMCs from HCV-infected HBV-NR and HBV-R or HS were incubated with αTim-3 and control IgG antibody for 72h, and then stimulated with PMA/ionomycin for 6h, followed by flow cytometry analysis of IL-17A expression in CD4+ T cells. Representative dot plots and summary data measuring IL-17 production by CD4+ T cells in HCV-infected HBV-NR versus HBV-R or HS with the blockade of Tim-3 or IgG antibody are shown. *P<0.05; **P<0.01; *** P<0.001; NS = no significance.